8-K: Stoke Therapeutics Accelerates Zorevunersen Trial Timelines

Stoke Therapeutics announced accelerated timelines for its Phase 3 EMPEROR study of zorevunersen for Dravet syndrome, with enrollment completion expected in Q2 2026 and data readout in mid-2027, alongside a strong cash position.

Summary

• Stoke Therapeutics expects to complete enrollment of 150 patients in its Phase 3 EMPEROR study for zorevunersen in the second quarter of 2026.
• A Phase 3 data readout is anticipated in mid-2027, which is expected to support the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA).
• The company plans to initiate a rolling NDA submission in the first half of 2027.
• Discussions with the FDA are ongoing regarding potential expedited regulatory pathways for zorevunersen, following a recent multidisciplinary meeting where no immediate changes to the development program were agreed upon.
• As of December 31, 2025, the company had approximately $391.7 million in cash, cash equivalents, and marketable securities.
• These funds, combined with eligible proceeds from the Biogen collaboration, are anticipated to fund operations into 2028.
• Zorevunersen has Breakthrough Therapy Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation for Dravet syndrome.
• The EMPEROR study is a global, double-blind, sham-controlled study evaluating zorevunersen in children aged 2 to <18 with Dravet syndrome caused by SCN1A gene mutations.

Sentiment

Score: 8

Explanation: The sentiment is positive due to accelerated clinical trial timelines for a key drug with Breakthrough Therapy Designation, strong cash runway into 2028, and ongoing constructive discussions with the FDA regarding expedited pathways. While no immediate changes were agreed with the FDA, the overall progress and financial stability are strong positives for a clinical-stage biotech.

Positives

• Accelerated timelines for Phase 3 EMPEROR study enrollment completion (Q2 2026) and data readout (mid-2027), potentially leading to earlier NDA submission.
• Strong cash, cash equivalents, and marketable securities balance of approximately $391.7 million as of December 31, 2025.
• Anticipated cash runway into 2028, combined with Biogen collaboration proceeds, provides financial stability.
• Ongoing discussions with the FDA to explore potential expedited regulatory pathways for zorevunersen.
• Zorevunersen holds Breakthrough Therapy Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation, highlighting its potential and unmet medical need.

Negatives

• No immediate changes to the zorevunersen development program were agreed to at the recent multidisciplinary meeting with the FDA.
• Preliminary financial information is an estimate and subject to audit adjustments, which may differ materially from actual results.

Risks

• Ability to advance, obtain regulatory approval of, and ultimately commercialize product candidates, including zorevunersen.
• Timing of data readouts and interim and final results of preclinical and clinical trials.
• Receipt and timing of potential regulatory decisions.
• Positive results in a clinical trial may not be replicated in subsequent trials or successes in early stage clinical trials may not be predictive of results in later stage trials.
• Ability to fund development activities and achieve development goals, including expectations regarding collaborations with Acadia Pharmaceuticals and Biogen International.
• Ability to protect intellectual property.
• Direct or indirect impact of global business, political and macroeconomic conditions, including inflation, tariffs, interest rate volatility, cybersecurity events, regulatory uncertainty, instability in the global banking system, volatile market conditions, public health crises, and ongoing geopolitical conflicts.

Future Outlook

The company anticipates completing enrollment for its Phase 3 EMPEROR study in Q2 2026, with a data readout expected in mid-2027 to support a rolling NDA submission planned for H1 2027. Discussions with the FDA are ongoing to explore potential expedited regulatory pathways for zorevunersen. The current financial position, combined with Biogen collaboration proceeds, is expected to fund operations into 2028.

Management Comments

• "The rate of enrollment in the Phase 3 EMPEROR study is highly encouraging and supports the significant need for a disease-modifying treatment for Dravet syndrome."
• "The accelerated timing for completion of enrollment of 150 patients, in addition to Breakthrough Therapy Designation, positions us to initiate a rolling NDA submission in the first half of 2027 resulting in the potential to deliver zorevunersen to patients sooner than originally expected."
• "Our recent multidisciplinary meeting was productive and we appreciate the FDA’s interest in deepening their understanding of Dravet syndrome and its impacts on patients and their families while also taking time to review and discuss our four years of clinical data."
• "We have responded to the Agency’s request for additional information and we look forward to continuing to engage with them as part of our commitment to explore every opportunity to deliver zorevunersen to patients as quickly as possible."

Industry Context

Dravet syndrome is a severe developmental and epileptic encephalopathy with significant unmet medical needs, as current anti-seizure medicines often fail to achieve substantial seizure reduction and do not address cognitive and behavioral impairments. Zorevunersen, as a potential first-in-class disease-modifying treatment, aims to address the underlying genetic cause by increasing functional NaV1.1 protein, positioning Stoke Therapeutics at the forefront of developing novel RNA-based therapies for haploinsufficiency disorders.

Stakeholder Impact

• Shareholders: Potential for increased valuation due to accelerated clinical progress and extended cash runway, but also subject to clinical trial risks.
• Patients with Dravet Syndrome: Potential for earlier access to a disease-modifying treatment if zorevunersen is approved, offering hope for improved outcomes.
• Employees: Continued stability and focus on advancing the lead program.
• Biogen (Collaborator): Continued progress in the joint development of zorevunersen.

Next Steps

• Complete enrollment of 150 patients in the Phase 3 EMPEROR study in Q2 2026.
• Initiate enrollment of at least 20 additional patients in Germany, Spain, France, and Italy for the EMPEROR study starting in Q2 2026.
• Continue discussions with the FDA regarding potential opportunities to expedite the development, registration, and delivery of zorevunersen.
• Initiate a rolling NDA submission in the first half of 2027.
• Report Phase 3 data readout in mid-2027.
• Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.

Key Dates

Recommendation

The accelerated timelines for the Phase 3 EMPEROR study, coupled with a robust cash position extending into 2028, significantly de-risk Stoke Therapeutics' lead program, zorevunersen. The drug's Breakthrough Therapy Designation and ongoing FDA discussions for expedited pathways further enhance its potential. While clinical trials inherently carry risk, these updates suggest a positive trajectory and reduced near-term funding concerns, making it an attractive opportunity for investors seeking exposure to innovative biotech with a clear path forward for its lead asset.

Keywords

Stoke Therapeutics, STOK, Zorevunersen, Dravet Syndrome, Phase 3 Clinical Trial, EMPEROR Study, FDA, NDA Submission, Biotechnology, RNA Medicine, Antisense Oligonucleotide, Breakthrough Therapy Designation, Clinical Development, Financial Guidance